Neurodevelopmental Impairment at Two Years in Premature Infants with Prolonged Patency of Ductus Arteriosus after a Conservative Approach

Abstract

Objective The study aims to assess the impact on neurodevelopmental outcomes of a prolonged hemodynamically significant patent ductus arteriosus (PDA) after a conservative treatment.

Study Design This involves the study of two cohorts of preterm infants 23 to 29 weeks gestation, before (n = 29) and after (n = 54) a conservative approach of PDA. We compared survival, major outcomes, and neurodevelopmental impairment (NDI) at 2 years and analyzed NDI in the conservative cohort according to the duration of the PDA.

Results Conservative cohort received less medical (31.5%) and surgical treatment (7.4%) and had more days of PDA (59 days in 24–26 weeks and 22 days in 27–29 weeks; p < 0.001) in comparison with control cohort (19 days in 24–26 weeks and 11 days in 27–29 weeks; p = 0.688). Mortality, survival-without-morbidity at discharge, and NDI at 2 years were similar between the two groups (p = 0.732). In the multivariate analysis PDA >28 days was not related to worse outcomes at discharge (p = 0.296) or less survival-without-NDI at 2 years (p = 0.498).

Conclusion Until randomized trials prove the benefit of attempting to close the PDA with ibuprofen in the first week of life, conservative management may be a reasonable option.

Keywords

conservative management - neurodevelopmental impairment - patent ductus arteriosus - preterm infant

Publikationsverlauf

Eingereicht: 02. Februar 2019

Angenommen: 23. August 2019

Artikel online veröffentlicht:
10. Oktober 2019

• References

• 1 Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006; 117 (04) 1113-1121
• 2 Nemerofsky SL, Parravicini E, Bateman D, Kleinman C, Polin RA, Lorenz JM. The ductus arteriosus rarely requires treatment in infants >1000 grams. Am J Perinatol 2008; 25 (10) 661-666
• 3 Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?. J Perinatol 2010; 30 (04) 241-252
• 4 Schena F, Francescato G, Cappelleri A. et al. Association between hemodynamically significant patent ductus arteriosus and bronchopulmonary dysplasia. J Pediatr 2015; 166 (06) 1488-1492
• 5 Edstedt Bonamy AK, Gudmundsdottir A, Maier RF. et al; Collaborators from the EPICE Research Group. Patent ductus arteriosus treatment in very preterm infants: a European Population-Based Cohort Study (EPICE) on variation and outcomes. Neonatology 2017; 111 (04) 367-375
• 6 Ngo S, Profit J, Gould JB, Lee HC. Trends in patent ductus arteriosus diagnosis and management for very low birth weight infants. Pediatrics 2017; 139 (04) e20162390
• 7 Bixler GM, Powers GC, Clark RH, Walker MW, Tolia VN. Changes in the diagnosis and management of patent ductus arteriosus from 2006 to 2015 in United States neonatal intensive care units. J Pediatr 2017; 189 (00) 105-112
• 8 Benitz WE. Committee on Fetus and Newborn, American Academy of Pediatrics. Patent ductus arteriosus in preterm infants. Pediatrics 2016; 137 (01) e20153730
• 9 Schmidt B, Davis P, Moddemann D. et al; Trial of Indomethacin Prophylaxis in Preterms Investigators. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001; 344 (26) 1966-1972
• 10 Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr 2007; 150 (03) 229-234
• 11 Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2013; 4 (04) CD003481
• 12 Weisz DE, McNamara PJ. Patent ductus arteriosus ligation and adverse outcomes: causality or bias?. J Clin Neonatol 2014; 3 (02) 67-75
• 13 Chock VY, Goel VV, Palma JP. et al. Changing management of the patent ductus arteriosus: effect on neonatal outcomes and resource utilization. Am J Perinatol 2017; 34 (10) 990-995
• 14 Semberova J, Sirc J, Miletin J. et al. Spontaneous closure of patent ductus arteriosus in infants ≤1500 g. Pediatrics 2017; 140 (02) e20164258
• 15 Slaughter JL, Reagan PB, Newman TB, Klebanoff MA. Comparative effectiveness of nonsteroidal anti-inflammatory drug treatment vs no treatment for patent ductus arteriosus in preterm infants. JAMA Pediatr 2017; 171 (03) e164354
• 16 Jhaveri N, Moon-Grady A, Clyman RI. Early surgical ligation versus a conservative approach for management of patent ductus arteriosus that fails to close after indomethacin treatment. J Pediatr 2010; 157 (03) 381-387 , 387.e1
• 17 El-Khuffash A, Weisz DE, McNamara PJ. Reflections of the changes in patent ductus arteriosus management during the last 10 years. Arch Dis Child Fetal Neonatal Ed 2016; 101 (05) F474-F478
• 18 McNamara P, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Childhood-Fetal Neonatal 2007; 92: F424-F427 . Accessed January 25, 2014 at http://fn.bmj.com/content/92/6/F424.short
• 19 Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163 (07) 1723-1729
• 20 Sánchez Luna M, Moreno Hernando J, Botet Mussons F. et al; Comisión de Estándares de la Sociedad Española de Neonatología. [Bronchopulmonary dysplasia: definitions and classifications]. An Pediatr (Barc) 2013; 79 (04) 262.e1-262.e6
• 21 Patz A. New international classification of retinopathy of prematurity. Pediatrics 1984; 74 (01) 160-161
• 22 Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978; 92 (04) 529-534
• 23 Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997; 39 (04) 214-223
• 24 Mitra S, Florez ID, Tamayo ME. et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants a systematic review and meta-analysis. JAMA 2018; 319 (12) 1221-1238
• 25 Sellmer A, Bjerre JV, Schmidt MR. et al. Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3. Arch Dis Child Fetal Neonatal Ed 2013; 98 (06) F505-F510
• 26 Noori S, McCoy M, Friedlich P. et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics 2009; 123 (01) e138-e144
• 27 Bancalari E, Claure N, Sosenko IRS. Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Semin Neonatol 2003; 8 (01) 63-71
• 28 Sung SI, Chang YS, Chun JY. et al. Mandatory closure versus nonintervention for patent ductus arteriosus in very preterm infants. J Pediatr 2016; 177: 66-71
• 29 Mohamed MA, El-Dib M, Alqahtani S, Alyami K, Ibrahim AN, Aly H. Patent ductus arteriosus in premature infants: to treat or not to treat?. J Perinatol 2016; 2017 (00) 1-6
• 30 Liebowitz M, Clyman RI. Prophylactic indomethacin compared with delayed conservative management of the patent ductus arteriosus in extremely preterm infants: effects on neonatal outcomes. J Pediatr 2017; 187 (187) 119-126
• 31 Bourgoin L, Cipierre C, Hauet Q. et al. Neurodevelopmental outcomes of preterm infants treated with oral paracetamol versus ibuprofen for patent ductus arteriosus. Neonatology 2016; 109 (01) 139-146
• 32 Wickremasinghe AC, Rogers EE, Piecuch RE. et al. Neurodevelopmental outcomes following two different treatment approaches (early ligation and selective ligation) for patent ductus arteriosus. J Pediatr 2012; 161 (06) 1065-1072
• 33 Davidson A. The effect of anaesthesia on the infant brain. Early Hum Dev 2016; 102 (02) 37-40
• 34 Paule MG, Li M, Allen RR. et al. Ketamine anesthesia during the first week of life can cause long-lasting cognitive deficits in rhesus monkeys. Neurotoxicol Teratol 2011; 33 (02) 220-230
• 35 Rolland A, Shankar-Aguilera S, Diomandé D, Zupan-Simunek V, Boileau P. Natural evolution of patent ductus arteriosus in the extremely preterm infant. Arch Dis Child Fetal Neonatal Ed 2015; 100 (01) F55-F58
• 36 Johnston PG, Gillam-Krakauer M, Fuller MP, Reese J. Evidence-based use of indomethacin and ibuprofen in the neonatal intensive care unit. Clin Perinatol 2012; 39 (01) 111-136
• 37 Van Overmeire B, Smets K, Lecoutere D. et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000; 343 (10) 674-681
• 38 Dani C. New therapeutic strategies for the treatment of patent ductus arteriosus. J Matern Fetal Neonatal Med 2011; 24 (Suppl. 01) 32-33